Nine years of influenza vaccination in an Argentinean company: Costs and benefits for the employer

International Congress Series

Volumn 1263, Issue C, 2004, Pages 590-594

  Santoro, N ^a   Tasset Tisseau, A ^b   Nicoloyanis, N ^c   Armoni, J ^d  

^a DUPONT COMPANY   (United States)

^b SANOFI PASTEUR   (France)

^c UNIVERSITÉ DE LYON   (France)

^d Aventis Pasteur   (Argentina)

Author keywords

Cost benefit; Influenza; Occupational health; Vaccination

Indexed keywords

EID: 84996583797     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2004.02.135     Document Type: Article

References (6)

1. Nichol, K.L., The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21:16 (2003), 1769–1775.
2. Nichol, K.L., Mallon, K.P., Mendelman, P.M., Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 21:17–18 (2003), 2216–2226.
3. Postma, M.J., et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 62:7 (2002), 1013–1024.
4. Burckel, E, et al. Economic impact of providing workplace influenza vaccination. Pharmacoeconomics 16 (1999), 563–576.
5. Demicheli, V, et al. Prevention and early treatment of influenza in healthy adults. Vaccine 18 (2000), 957–1030.
6. A. Morales, et al., Influenza vaccination and work productivity in a Colombian company: What are the costs and benefits for the employer? ISPOR Congress, Rotterdam, Nov 2002, poster PIN 24.